News & ViewsNewslettersContactBecome a Research Patient
DHRHealth Institute for Research and Development

Clinical Trial

A Phase 3, Multicenter, Randomized, Double-Blind, Parallel-Arm, Placebo-Controlled Maintenance Study of Mirikizumab in Patients with Moderately to Severely Active Ulcerative Colitis LUCENT 2

Study Status:

Active

Please contact us for more information or to learn if you are eligible to participate.

Study Purpose:

The purpose of this study is to evaluate the safety and efficacy of mirikizumab in maintaining remission at Week 40 in patients who completed the 12-week iduction study 16T-MC-AMAN.

Information: 

Principal Investigator
Sriramachandra Badiga, MD
Type of Trial
Prospective/Interventional
DHRHealth Institute for Research and Development
5323 S. McColl Rd., Edinburg, TX 78539
(956) 362-2390
© 2022 DHR Health Institute for Research & Development | All Rights Reserved | Terms & Conditions | Site By: KangoMedia
chevron-down linkedin facebook pinterest youtube rss twitter instagram facebook-blank rss-blank linkedin-blank pinterest youtube twitter instagram